Experts said the approval of the new treatment combination would bring a ‘fundamental shift’ in care for patients with late-stage disease.

MDMA (Molly, ecstasy) is an empathogen widely used as a club drug that may become a future treatment for PTSD. Many respond ...

The AI-enabled bundled system used sensors and coaching to guide patients. It generated personalized recommendations by ...

The FDA granted breakthrough therapy designation to Ifinatamab deruxtecan for some with extensive-stage small cell lung ...

Merck’s MRK strong foothold in the oncology space is propelled by its biggest revenue driver, Keytruda. The blockbuster PD-L1 ...

Merck’s strong oncology gains, 4% yield, and low PEG ratio support its value case despite sector risks and patent concerns.

EdiMembre has spun off from Merck Group to commercialise its edible membrane tech for future foods, starting with whole-cut ...

New Jersey officials are eyeing several efforts, including a massive $500 million incentive program meant to entice more products to be "Made in NJ." ...

Janux Therapeutics Inc. (NASDAQ:JANX) is a clinical-stage biopharmaceutical company that develops immunotherapies based on ...

Pfizer is a solid dividend stock. Its forward yield currently tops 7%, and the company has increased its payouts by 19.5% in ...

The Nobel Prize-winning technology underpinning COVID-19 vaccines is also fueling a host of biotechs developing treatments ...

Manufacturing in Ireland has long helped many American drug companies pay lower taxes. But that strategy was designed for a ...